

UNDER THE AUSPICES OF



ROME MAY 7/8, 2023
SECOND INTERNATIONAL
SUMMIT ON LUNG CANCER

SCIENTIFIC COMMITTEE
FEDERICO CAPPUZZO - SILVIA NOVELLO

SCIENTIFIC SECRETARIAT
LORENZA LANDI - GABRIELE MINUTI

SCIENTIFIC COMMITTEE

FEDERICO CAPPUZZO

Oncology Department Director
Istituto Nazionale Tumori "Regina Elena"
Rome, Italy

SILVIA NOVELLO

Professor of Medical Oncology
Oncology Department AOU San Luigi
University of Turin
Italy

SCIENTIFIC SECRETARIAT

LORENZA LANDI

Head of the UOSD Clinical Trials: Phase 1 and Precision Medicine
Istituto Nazionale Tumori "Regina Elena"
Rome, Italy

GABRIELE MINUTI

Physician of the Phase 1 UOSD and Precision Medicine
Istituto Nazionale Tumori "Regina Elena"
Rome, Italy

DAY 1 | MAY 7, 2023

09.00 **Welcome by authorities**

09.10 Lecture **The evolving landscape of lung cancer** Giorgio V. Scagliotti

PREVENTION AND EARLY DETECTION OF LUNG CANCER

Chairs: Lucio Crinò, Fred Hirsch

09.40 **Expert's opinion** Fred Hirsch

09.45 **Tobacco cessation among patients with lung cancer** April Plank

09.55 **Early detection of lung cancer** Ugo Pastorino

10.05 Panel Discussion

Lucio Crinò, Fred Hirsch, Ugo Pastorino, April Plank

LIQUID BIOPSY AND NEW BIOMARKERS

Chairs: Jair Bar, Simonetta Buglioni, Giuseppe Perrone, Gabriella Sozzi

10.20 **Expert's opinion** Gabriella Sozzi

10.25 **Liquid biopsy for screening and early detection** Christian Rolfo

10.35 **Practical applications of liquid biopsy** Natasha Leighl

10.45 **Liquid biopsy for guiding therapy decision** Umberto Malapelle

10.55 **Neoantigen landscape and Tumor Mutational Burden** Patrick Alexander Ott

11.05 Panel Discussion

Jair Bar, Simonetta Buglioni, Natasha Leighl, Umberto Malapelle, Patrick Alexander Ott, Giuseppe Perrone, Christian Rolfo, Gabriella Sozzi

NEOADJUVANT THERAPY OF LUNG CANCER

Chairs: Francesco Facciolo, Domenico Galetta, Francesco Grossi

11.20 **Expert's opinion** Francesco Grossi

11.25 **Chemoimmunotherapy in resectable NSCLC** Bartomeu Massuti

11.35 **PD-L1 expression and efficacy of neoadjuvant chemoimmunotherapy** Patrick Forde

11.45 **Neoadjuvant chemoimmunotherapy and tumor stage** Jonathan Spicer

11.55 **Post-surgery options** Nicolas Girard

12.05 **Role of MRD** Nicola Normanno

12.15 Panel Discussion

Francesco Facciolo, Patrick Forde, Domenico Galetta, Nicolas Girard, Francesco Grossi, Bartomeu Massuti, Nicola Normanno, Jonathan Spicer

12.30 Lunch



ADJUVANT THERAPY

Chairs: Antonio D'Andrilli, Anne-Marie C. Dingemans, Simon Ekman, Giorgio V. Scagliotti, Piergiorgio Solli

13.20 **Expert's opinion** Anne-Marie C. Dingemans

13.25 **Anti-EGFR agents in the adjuvant setting** Yi-Long Wu

13.35 **Options for non-EGFR mutant/oncogene addicted resected NSCLC** Christian Grohe

13.45 **Adjuvant immunotherapy** Maurice Perol

13.55 **PD-L1 expression and choice of adjuvant immunotherapy** Enriqueta Felip Font

14.05 **Panel Discussion**

Antonio D'Andrilli, Anne-Marie C. Dingemans, Simon Ekman, Enriqueta Felip Font, Christian Grohe, Maurice Perol, Giorgio V. Scagliotti, Piergiorgio Solli, Yi-Long Wu

INTEGRATED THERAPIES FOR STAGE III NSCLC

Chairs: Raffaele Califano, Alessandra Cancellieri, Andrea Filippi, Sara Ramella

14.20 **Expert's opinion** Sara Ramella

14.25 **Challenges in staging N2 disease** Rocco Trisolini

14.35 **Radiotherapy for N2 resected NSCLC** Cecile Le Pechoux

14.45 **Impact of neoadjuvant chemoimmunotherapy in management of stage III NSCLC** Marcello Tiseo

14.55 **Maintenance immunotherapy in stage III unresectable NSCLC** Umberto Ricardi

15.05 **Panel Discussion**

Raffaele Califano, Alessandra Cancellieri, Andrea Filippi, Cecile Le Pechoux, Sara Ramella, Umberto Ricardi, Marcello Tiseo, Rocco Trisolini

15.20 **Lecture Neoadjuvant immunotherapy in lung cancer** Tina Cascone

16.20 **Conclusion first day**

DAY 2
MAY 8, 2023

IMMUNOTHERAPY FOR FIRST-LINE NSCLC

Chairs: Lorenza Landi, Mariarita Migliorino, Rolf Stahel, H. Jack West

09.00 **Expert's opinion** Rolf Stahel

09.05 **Monoimmunotherapy for advanced NSCLC PD-L1 >50%:** Jair Bar

09.15 **Monoimmunotherapy or chemoimmunotherapy in PD-L1>50%** Solange Peters

09.25 **Immunotherapy options for squamous-cell lung cancer** Rafal Dziadziuszko

09.35 **Immunotherapy for unfit NSCLC** Siow Ming Lee

09.45 **Combination with anti-CTLA4** Luis Paz-Ares Rodríguez

09.55 **New immunotherapy combinations** Delvys Rodriguez-Abreu

10.05 **Immunotherapy combinations for KRAS G12C mutant NSCLC** Dolores Isla

10.15 **Panel Discussion**

Jair Bar, Rafal Dziadziuszko, Dolores Isla, Lorenza Landi, Mariarita Migliorino, Siow Ming Lee, Luis Paz-Ares Rodríguez, Solange Peters, Delvys Rodriguez-Abreu, Rolf Stahel, H. Jack West

EMERGING OPTIONS IN IMMUNE-PRETREATED NSCLC

Chairs: Federico Cappuzzo, Keunchil Park, Francesco Passiglia

10.35 **Expert's opinion** Hossein Borghaei

10.40 **Mechanisms of resistance to immunotherapy** Paola Nisticò

10.50 **Novel strategies for overcoming resistance to checkpoint inhibitors**
Naiyer Rizvi

11.00 **Targeting TAM receptors in immune-pretreated NSCLC** Ross Soo

11.10 **ADC in pretreated NSCLC** Federico Cappuzzo

11.20 **Panel Discussion**

Hossein Borghaei, Federico Cappuzzo, Paola Nisticò, Keunchil Park, Francesco Passiglia, Naiyer Rizvi, Ross Soo

THE COLOSSEUM

Called by the ancient Romans, "Anphitheatrum Flavium" (Flavian Amphitheatre), the Colosseum is the most famous and impressive monument of ancient Rome, as well as the largest amphitheater in the world. The name is undoubtedly linked to the large size of the building but derives above all from the fact that nearby there was a colossal statue of Nero and bronze.

In 1990, the **Colosseum**, along with all the historical center of Rome, the Vatican extraterritorial zones in Italy and the Basilica of St. Paul Outside the Walls, was listed as a World Heritage Site by UNESCO, while in July 2007 was included among the New seven Wonders of the World..

BETWEEN IMMUNOTHERAPY AND TARGET THERAPY-ROLE OF KRAS

Chairs: Mark M. Awad, Ruggero De Maria, Stephen Liu, Paolo Marchetti, Konstantinos Syrigos

11.35 **Expert's opinion** Stephen Liu

11.40 **KRAS and co-mutations. Impact of STK11 or KEAP1** Ferdinandos Skoulidis

11.50 **Agents targeting KRAS G12C** Silvia Novello

12.00 **KRAS inhibitors: Single agent or in combination?** Konstantinos Syrigos

12.10 **Emerging agents in KRAS mutated** Paolo Bironzo

12.20 Panel Discussion

Mark M. Awad, Paolo Bironzo, Ruggero De Maria, Stephen Liu, Paolo Marchetti, Silvia Novello, Ferdinandos Skoulidis, Konstantinos Syrigos

12.35 Lunch

TARGETED THERAPIES FOR NSCLC

Chairs: Benjamin Besse, Emilio Bria, Federico Cappuzzo, Jordi Remon Masip

13.35 **Expert's opinion** Federico Cappuzzo

13.40 **Standard options for EGFR mutant NSCLC** Pasi A. Janne

13.50 **EGFR inhibitors in combination with anti-angiogenic agents** Pilar Garrido

14.00 **Impact of p53 co-mutations on EGFR-TKI efficacy** Benjamin Besse

14.10 **Drugging exon 20 mutations** Rosario Garcia Campelo

14.20 **New drugs for HER2 deregulated NSCLC** Egbert Smit

14.30 **Options for BRAF mutant patients** David Planchard

14.40 **Options for MET exon 14 mutated patients** Jordi Remon Masip

14.50 **Best first-line agent for ALK + NSCLC** Sai-Hong Ignatius Ou

15.00 **Options for ROS1+ NSCLC** Lorenza Landi

15.10 **Options for NTRK rearranged tumors** Roberto Ferrara

15.20 **RET inhibitors in lung cancer** Rita Chiari

15.30 **NRG1: a new target in NSCLC** Gabriele Minuti

15.40 Panel Discussion

Benjamin Besse, Emilio Bria, Federico Cappuzzo, Rita Chiari, Roberto Ferrara, Rosario Garcia Campelo, Pilar Garrido, Pasi A. Janne, Lorenza Landi, Gabriele Minuti, Sai-Hong Ignatius Ou, David Planchard, Jordi Remon Masip, Egbert Smit

SMALL CELL LUNG CANCER AND MESOTHELIOMA

Chairs: Andrea Ardizzoni, Fabiana Cecere, Sara Pilotto

16.00 **Expert's opinion** Jordi Remon Masip

16.05 **Immunotherapy as first-line therapy in SCLC** Andrea Ardizzoni

16.15 **Immunotherapy combinations as first-line therapy in SCLC** Charles Rudin

16.25 **Immunotherapy for patients with pleural mesothelioma** Federica Grosso

16.35 Panel Discussion

Andrea Ardizzoni, Fabiana Cecere, Federica Grosso, Sara Pilotto, Charles Rudin

16.50 Closing Lecture **Rediscovering IHC in lung cancer** Keith Kerr

17.20 **Closing remarks** Federico Cappuzzo

ST. PETER'S BASILICA

The Papal Basilica of Saint Peter in the Vatican or simply Saint Peter's Basilica is a church built in the Renaissance style located in Vatican City, the papal enclave that is within the city of Rome. It was initially planned by Pope Nicholas V and then Pope Julius II to replace the aging Old St. Peter's Basilica, which was built in the 4th century by Roman emperor Constantine the Great. Construction of the present basilica began on 18 April 1506 and was completed on 18 November 1626. Designed principally by Donato Bramante, Michelangelo, Carlo Maderno and Gian Lorenzo Bernini, St. Peter's is the most renowned work of Renaissance architecture and the largest church in the world by interior measure.

FACULTY

Andrea Ardizzoni
Bologna - I

Mark M. Awad
Boston - US

Jair Bar
Tel Aviv - IL

Benjamin Besse
Paris- F

Paolo Bironzo
Turin - I

Hossein Borghaei
Philadelphia - US

Emilio Bria
Rome - I

Simonetta Buglioni
Rome - I

Raffaele Califano
Manchester - UK

Alessandra Cancellieri
Rome - I

Federico Cappuzzo
Rome - I

Tina Cascone
Houston - US

Fabiana Letizia Cecere
Rome - I

Rita Chiari
Schiavonia - I

Lucio Crinò
Meldola/Forlì - I

Antonio D'Andrilli
Rome - I

Ruggero De Maria
Rome - I

Anne-Marie C. Dingemans
Maastricht -NL

Rafal Dziadziuszko
Danzica - PL

Simon Ekman
Uppsala - S

Francesco Facciolo
Rome - I

Enriqueta Felip Font
Barcelona - E

Roberto Ferrara
Milan - I

Andrea Riccardo Filippi
Pavia - I

Patrick Forde
Baltimora - US

Domenico Galetta
Bari - I

Rosario Garcia Campelo
Coruña - E

Pilar Garrido Lopez
Madrid - E

Nicolas Girard
Paris- F

Christian Grohe
Berlin - I

Francesco Grossi
Varese - I

Federica Grosso
Alessandria - I

Fred Hirsch
New York - US

Pasi A. Janne
Boston - US

Keith Kerr
Aberdeen - UK

Lorenza Landi
Rome - I

Cecile Le Pechoux
Paris- F

Natasha Leighl
Toronto - CDN

Dolores Isla
Saragozza - E

Stephen Liu
Georgetown - US

Umberto Malapelle
Naples - I

Paolo Marchetti
Rome - I

Bartomeu Massuti
Alicante - E

Maria Rita Migliorino
Rome - I

Siow Ming Lee
London - UK

Gabriele Minuti
Rome - I

Paola Nisticò
Rome - I

Nicola Normanno
Naples - I

Silvia Novello
Turin - I

Patrick Alexander Ott
Boston - US

Sai-Hong Ignatius Ou
Orange - US

Keunchil Park
Seoul - ROK

Francesco Passiglia
Turin - I

Ugo Pastorino
Milan - I

Luis Paz-Ares Rodríguez
Madrid - E

Maurice Perol
Lione - F

Giuseppe Perrone
Rome - I

Solange Peters
Lausanne - CH

Sara Pilotto
Verona - I

David Planchard
Villejuif - F

April Plank
New York - US

Sara Ramella
Rome - I

Jordi Remon Masip
Paris- F

Umberto Ricardi
Turin - I

Naiyer Rizvi
San Francisco - US

Delvys Rodriguez-Abreu
Gran Canaria - E

Christian Rolfo
New York - US

Charles Rudin
New York - US

Giorgio Vittorio Scagliotti
Turin - I

Ferdinandos Skoulidis
Houston - US

Egber Smit
Leida - NL

Piergiorgio Solli
Bologna - I

Ross Soo
Singapore - MY

Gabriella Sozzi
Milan - I

Jonathan Spicer
Montreal Trudeau - CDN

Rolf Stahel
Zurich - CH

Marcello Tiseo
Parma - I

Rocco Trisolini
Rome - I

Howard Jack West
Duarte - US

Yi-Long Wu
Guangdong - RC

GENERAL INFORMATION

This event will take place only in person.

VENUE

Hotel Le Meridien Visconti Rome

Via Federico Cesi, 37 Rome

REGISTRATION

Registration is free of charge.

Please complete the process to register at our site www.mitcongressi.it

Have a question about the upcoming conference?

Email: segreteria@mitcongressi.it

14 ECM FOR ITALIAN PARTICIPANTS ONLY

Medical specialties:

Pharmacy

Biology

Biomedical Technician

Medical Radiology Technician

Medical Physic

Surgeon Allergy and Immunology - Anatomic and Clinical Pathology - Anesthesiology - General Surgery - Thoracic Surgery - Palliative Medicine - Hospital Clinical management - Pharmacology and Medical Toxicology - Genetics - Pulmonary Disease - Internal Medicine - Nuclear Medicine - Oncology - Pathology - Radiation Oncology - Diagnostic Radiology

Cardiocirculatory and Cardiovascular Perfusion Technitian

Nurse

CME INSTRUCTIONS

The CME Questionnaire and Certificate of Participation will be available online by accessing our platform in the "My courses" section of your reserved area. For the purpose of acquiring credits, you will need 90% in person attendance and a score of 75% or higher on the learning assessment questionnaire. You must have both in person attendance and questionnaire completion to obtain credit. The deadline for the completion of the ECM assessment questionnaire and the course approval questionnaire is set within 72 hours from the end of the course.

ORGANIZATIONAL SUPPORT

Anna Maria Edilisca

PROVIDER AND LOGISTIC SECRETARIAT



MI&T srl - Centro Direzionale Bolomnia

Via Guelfa, 5 - 40138 Bologna

info@mitcongressi.it - www.mitcongressi.it

UNRESTRICTED GRANT BY

PLATINUM



GOLD



SILVER



BRONZE

